Trial Profile
Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Acenocoumarol
- Indications Antiphospholipid syndrome; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2019 Results determining whether rivaroxaban is non inferior to dose-adjusted Vitamin K antagonists for Thrombotic Antiphospholipid Syndrome published in the Annals of Internal Medicine
- 24 Oct 2018 Primary endpoint has not been met. (Incidence of major bleeding)
- 24 Oct 2018 Primary endpoint has not been met. (Developement of a new thrombotic event (arterial or venous), confirmed by appropiate imaging studies)